Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in...

Prof Georgina Long - University of Sydney, Sydney, Australia

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Safety and efficacy of atezolizumab plus bevacizumab for unresectable...

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

First-line pembrolizumab plus chemotherapy for patients with advanced squamous...

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General...

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea

Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )

Highlights from AORTIC Cancer Genomics Conference 2021

Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center...

Highlights from AORTIC Cancer Genomics Conference 2021 ( Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, Accra, Ghana )

The Conquering Cancer Campaign

Prof Karen Canfell - University of Sydney, Sydney, Australia

The Conquering Cancer Campaign ( Prof Karen Canfell - University of Sydney, Sydney, Australia )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

More from ecancer